Navigation Links
Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
Date:3/12/2013

NEWTON, Mass., March 12, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, announced today that it has entered into an exclusive license agreement with the University of Bristol.  Under the terms of the agreement, the Company has acquired exclusive worldwide rights to use, for all skin applications, a novel method to manufacture a class of prostaglandins that reduces fat.  Additional terms were not disclosed. 

The revolutionary technology, which one expert has called "unbeatable in its conciseness and elegance", greatly simplifies synthesis of prostaglandins.  It is expected to improve manufacturing efficiency by 5-10 fold and substantially reduce manufacturing costs.  The technology, featured in the September 13th, 2012 issue of Nature magazine, was developed at the University of Bristol by Professor Varinder Aggarwal and colleagues.

"There is remarkable synergy between our research and Topokine's innovative products.  I look forward to helping advance Topokine's efforts by applying our synthesis technology," said Professor Aggarwal, a Fellow of the Royal Society who has joined Topokine's Advisory Board.

"Professor Aggarwal's group is at the cutting-edge of prostaglandin chemistry," said Murat Kalayoglu, MD, PhD, Topokine President & CEO.  "This exclusive license further enhances our IP position, and we are excited to collaborate with him and the University of Bristol."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat.  XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors.  XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About the University of Bristol

The University of Bristol is consistently ranked among the leaders in UK higher education.  Research-intensive and with an international reputation for quality and innovation, the University has over 18,000 students from over 100 countries, together with more than 5,000 staff.  Places at Bristol are among the most highly sought after of all UK universities.  The University was founded in 1876 and was granted its Royal Charter in 1909.  It was the first university in England to admit women on the same basis as men.  It is located in the heart of the city from which it grew, but is now a significant player on the world stage as well as a major force in the economic, social and cultural life of Bristol and South West England.  Bristol is a member of the Worldwide Universities Network and of the Russell Group of leading research-intensive universities in the UK.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., murat.kalayoglu@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
2. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
3. Shire Acquires Premacure AB
4. BD Acquires Cato Software Solutions
5. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
6. Dynamic Healthcare Services Acquires the operating assets of APO2, a Provider of Home Medical Equipment and Respiratory Therapy Products and Services in Hazleton, PA
7. PRA Acquires ClinStar
8. Endexx Acquires Medical Marijuana Management Technology
9. DSI Renal Acquires New Smyrna Beach Artificial Kidney Center
10. Henry Schein Acquires The Maddox Practice Group
11. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):